Inventor
Michael R. Johnson
Inventor
Chapel Hill, NC, US
Overview
Patents· 181 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium9%
Y02ATechnologies for adaptation to climate change3%
C07BGeneral methods of organic chemistry2%
C07HSugars2%
B63BShips or other waterborne vessels2%
A61MDevices for introducing media into, or onto, the body1%
PatentTitleYear
10,899,746Bisamide sarcomere activating compounds and uses thereof202110,894,052Heterocyclic inhibitors of ATR kinase202110,752,5973,5-diamino-6-chloro-N--(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide202010,526,292Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases202010,526,283Prodrugs of dithiol mucolytic agents202010,335,558Methods of treatment201910,246,4253,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds201910,233,158Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds201910,167,266Sodium channel blockers201910,159,672Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity201810,106,551Monothiol mucolytic agents201810,071,970Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity20189,987,443Inhaled hypertonic saline delivered by a heated nasal cannula20189,963,427Dithiol mucolytic agents20189,957,238Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds20189,878,988'Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases'20189,856,224'Stable sodium channel blockers'20189,849,129Sodium channel blockers for skin disorders20179,695,134'3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds'20179,655,896'Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity'20179,593,084'Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity'20179,586,910'3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide'20179,586,911'Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds'20179,408,988'Inhaled hypertonic saline delivered by a heated nasal cannula'20169,346,753'Dithiol mucolytic agents'20169,260,398'Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases'20169,102,633'Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds'20159,072,738'Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity'20159,029,382'3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds'20158,980,898'Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases'20158,945,605'Aerosol delivery systems, compositions and methods'20158,846,688'Sodium channel blockers'20148,778,383'Methods of treatment'20148,676,606'Systems and methods for providing comprehensive pharmaceutical consultations'20148,669,262'3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide'20148,589,186'Systems and methods for determining pharmaceutical consultation compliance'20138,575,176'Heteroaromatic pyrazinoylguanidine sodium channel blockers'20138,551,534'Inhaled hypertonic saline delivered by a heated nasal cannula'20138,545,636'Conductivity control of water content in solvent strip baths'20138,507,497'Capped pyrazinoylguanidine sodium channel blockers'20138,431,579'Capped pyrazinoylguanidine sodium channel blockers'20138,324,218'Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity'20128,314,105'Methods of reducing risk of infection from pathogens'20128,288,391'Pyrazinoylguanidine compounds for use as taste modulators'20128,227,474'Sodium channel blockers'20128,211,895'Capped pyrazinoylguanidine sodium channel blockers'20128,198,286'Sodium channel blockers'20128,163,758'Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity'20128,143,256'Cyclic amide and ester pyrazinoylguanidine sodium channel blockers'20128,124,607'Poly aromatic pyrazinoylguanidine sodium channel blockers'20128,058,278'Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes'20118,022,210'Soluble amide and ester pyrazinoylguanidine sodium channel blockers'20118,008,494'Soluble amide and ester pyrazinoylguanidine sodium channel blockers'20117,981,898'Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes'20117,956,059'Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers'20117,875,619'Hetero substituted sodium channel blockers'20117,868,010'Capped pyrazinoylguanidine sodium channel blockers'20117,842,697'Soluble amide and ester pyrazinoylguanidine sodium channel blockers'20107,820,678'Sodium channel blockers'20107,807,834'Capped pyrazinoylguanidine sodium channel blockers'20107,745,442'Methods of reducing risk of infection from pathogens'20107,410,968'Capped pyrazinoylguanidine sodium channel blockers'20087,399,766'Soluble amide & ester pyrazinoylguanidine sodium channel blockers'20087,388,013'Capped pyrazinoylguanidine sodium channel blockers'20087,375,107'Alaphatic pyrazinoylguanidine sodium channel blockers'20087,368,451'Capped pyrazinoylguanidine sodium channel blockers'20087,368,450'Sodium channel blockers'20087,368,447'Capped pyrazinoylguanidine sodium channel blockers'20087,345,044'Sodium channel blockers'20087,332,496'Methods of using sodium channel blockers'20087,317,013'Cyclic pyrazinoylguanidine sodium channel blockers'20087,247,636'Phenolic guanidine sodium channel blockers'20077,247,637'Capped pyrazinoylguanidine sodium channel blockers'20077,241,766'Methods of using phenolic guanidine sodium channel blockers'20077,192,958'Sodium channel blockers'20077,192,960'Sodium channel blockers'20077,192,959'Sodium channel blockers'20077,189,719'Sodium channel blockers'20077,186,833'Sodium channel blockers'20077,064,129'Capped pyrazinoylguanidine sodium channel blockers'20067,030,117'Sodium channel blockers'20067,026,325'Sodium channel blockers'20066,995,160'Sodium channel blockers'20066,903,105'Sodium channel blockers'20056,861,059'Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations'20056,858,615'Phenyl guanidine sodium channel blockers'20056,858,614'Phenolic guanidine sodium channel blockers'20056,713,580'Quaternary amino acids on solid supports'20046,475,491'Treatment of HIV and other viral infections using combinatorial therapy'20025,318,976'Cyclic antitumor compounds'19945,223,506'Cyclic antitumor compounds'19935,192,757'Cobalt porphyrins'19935,149,697'Cobalt porphyrin pharmaceutical compositions'19925,144,034'Process for the synthesis of cyclopentene derivatives of purines'19925,126,351'Antitumor compounds'19925,019,583'N-phenyl-N-(4-piperidinyl)amides useful as analgesics'19915,011,934'Process for preparing 1-alkylimidazoles'19914,968,707'Oxazolidin-2-one derivatives as hypoglycemic agents'19904,933,475'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19904,921,994'Pharmacologically active 2-hydroxy-4-(substituted) phenyl cycloalkanes and derivatives thereof'19904,920,221'Substituted decahydro-1H-pyrido[1,2-f]phenanthridines and decahydropyrrolo[1,2-f]phenanthridines'19904,870,084'Bicyclic benzo fused pyran compounds used for nausea treatment and prevention'19894,863,934'Bicyclic benzo fused pyran compounds used for producing analgesia'19894,841,078'Benzopyrans'19894,835,192'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19894,831,059'Producing analgesia with pharmacologically active 2-hydroxy-4-(substituted) phenyl cycloalkanes derivatives'19894,738,972'Hypoglycemic thiazolidinediones'19884,739,079'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19884,680,404'Benzopyrans'19874,642,373'Substituted dodecahydrotripheylenes, and decahydropyrrolo[1,2-f]phenanthridines as CNS agents'19874,593,131'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19864,576,964'Substituted hexahydrobenzo[e]indene and octahydrophenanthrene CNS agents and pharmaceutical compositions thereof'19864,529,732'2-[2-hydroxy-4-(substituted)phenyl]piperidines'19854,486,609'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19844,486,428'Bicyclic benzo fused compounds'19844,476,131'Substituted hexahydropyrrolo[1,2-a]-quinolines, hexahydro-1H-pyrido[1,2-a]- q'19844,473,704'Substituted dodecahydrotriphenylenes, decahydro-1H-cyclopenta[1]phenanthrenes, decahydro-1H-pyrido[1,2-f]phenanthridines and decahydropyrrolo[1,2-f]phenanthridines as CNS agents'19844,455,421'11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins'19844,454,144'Substituted dibenzo[b,d]pyran analgesics'19844,405,626'9-Hydroxyoctahydrobenzo(c)quinolines analgesic compositions containing them and processes for producing analgesic with them'19834,404,372'15-Substituted-.omega.-pentanorprostaglandin derivatives'19834,400,385'9-Hydroxyoctahydrobenzo [c]quinolines, analgesic compositions containing them and processes for producing analgesia with them'19834,391,827'3-(2-Hydroxy-4-(substituted)phenyl)-cycloalkanone and cycloalkanol analgesic agents and intermediates therefor'19834,387,229'3-[2-Hydroxy-4-(substituted)phenyl]azacycloalkanols and derivatives thereof'19834,380,542'9-Hydroxyoctahydrobenzo[c]quinolines and their pharmaceutical compositions and method of use'19834,379,783'Trialkylsilicon-containing phenylcycloalkane analgesics'19834,371,720'2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives'19834,365,077'11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins'19824,351,833'9-Amino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof as analgesics and anti-emetics'19824,342,868'2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-( 2-furyl)-.omega.-trisnorprostaglandin E.sub.2'19824,341,906'1,9-Dihydroxyoctahydrophenanthrenes'19824,340,737'9-Hydroxyoctahydrobenzo[C]quinolines and intermediates therefor'19824,332,942'3-(2-Hydroxy-4-(substituted)phenyl)azacycloalkanes as analgesics'19824,331,602'Pharmacologically active 4-[2-hydroxy-4-(substituted]phenyl)naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19824,310,669'Intermediates to 1,9-dihydroxyoctahydrophenanthrenes'19824,310,529'Intermediates to 1,9-dihydroxyoctahydrophenanthrenes'19824,310,668'Intermediates to 1,9-dihydroxyoctahydrophenanthrenes'19824,309,545'Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof'19824,306,097'3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents'19814,285,867'Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor'19814,284,829'Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives'19814,283,569'Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives'19814,270,005'1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor'19814,268,692'1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor'19814,268,523'1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor'19814,263,438'3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics'19814,260,764'9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor'19814,244,887'Substituted .omega.-pentanorprostaglandins'19814,243,595'15-Substituted-omega-pentanorprostaglandins'19814,237,133'1,9-Dihydroxyoctahydrophenanthrenes'19804,235,913'9-Hydroxyhexahydrodibeno[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo]b,d]pyrans'19804,232,018'Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents'19804,228,169'1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones as antiemetic agents'19804,209,520'Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents'19804,206,225'2,10-Disubstituted dibenzo[b,d]pyrans and benzo[c]quinolines'19804,188,495'1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor'19804,169,895'Antisecretory 16,16-dimethyl-17-oxaprostaglandins'19794,165,323'9-Hydroxyhexahydrodibenzo[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo[b,d]pyrans and intermediates therefor'19794,157,341'11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins'19794,154,949'11-Desoxy-15-substituted-.omega.-pentanor prostaglandins'19794,147,872'3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor'19794,143,051'15-Substituted-.omega.-pentanorprostaglandins'19794,133,819'Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents'19794,118,559'9-Hydroxyhexahydrodibenzo[O,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo[b,d]pyrans and intermediates therefor'19784,113,723'15-Substituted-.omega.-pentanorprostaglandins'19784,102,894'15-Substituted-.omega.-pentanorprostaglandins'19784,087,604'Substituted .omega.-pentanorprostaglandins'19784,080,368'Furyl-2-oxo-alkanephosphonates'19784,036,832'15-Substituted-.omega.-pentanorprostaglandins'19774,035,360'Magnesium salts of 2-descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanopro staglandins'19774,024,179'Substituted .omega.-pentanorprostaglandins'19774,018,758'3-Aminomethylene-6,7-dimethoxy-2-methyl-4-oxo-1,2,3,4-t etrahydro-1-quinoline carboxylic acid esters and intermediates leading thereto'19774,011,262'13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins of the two series'19773,984,424'P-biphenyl esters of 15-substituted-.omega.-pentanorprostaglandins'19763,980,642'15-Substitute D-.omega.-pentanorprostaglandins'19763,978,064'3-Aminomethylene-6,7-dimethoxy-2-methyl-4-ox o-1,2,3,4-tetrahydro-1-quinoline carboxylic acid esters and intermediates leading thereto'19763,976,650'Process for preparing optically active 6,7-dimethoxy-2-methyl-4-oxo-1,2,3,4-tetrahydro-1-quinoline carboxylic acid ester analgesics'19763,974,213'13,14-Dihydro-15-substituted-.omega.-pentanorprostaglandins'19763,971,826'15-Substituted-.omega.-pentanorprostaglandins'19763,956,284'Heterocyclic 15-substituted-.omega.-pentanorprostoglandins'19763,932,389'2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.ome ga.-pentanorprostaglandins'1976Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1976–1990Patents assigned to PFIZER (84)· patent assignee history
1976–1990Based in Gales Ferry, CT, US· patent location history
1990–2020Based in Chapel Hill, NC, US· patent location history
1991–1994Patents assigned to GLAXO INC (7)· patent assignee history
2005–2020Patents assigned to PARION SCIENCES INC (81)· patent assignee history
2005–2017Based in Durham, NC, US· patent location history
2011–2015Patents assigned to JOHNSON MICHAEL ROSS (9)· patent assignee history
2012–2014Patents assigned to JOHNSON MICHAEL R (12)· patent assignee history
2013–2014Based in Hobart, IN, US· patent location history
2021Based in San Francisco, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| PFIZER | 84 | 1976–1990 |
| PARION SCIENCES INC | 81 | 2005–2020 |
| JOHNSON MICHAEL Rself | 12 | 2012–2014 |
| JOHNSON MICHAEL ROSSself | 9 | 2011–2015 |
| GLAXO INC | 7 | 1991–1994 |
Locations
| Location | Patents | Span |
|---|---|---|
| Chapel Hill, NC, US | 81 | 1990–2020 |
| Gales Ferry, CT, US | 79 | 1976–1990 |
| Durham, NC, US | 10 | 2005–2017 |
| San Francisco, California, US | 2 | 2021 |
| Hobart, IN, US | 2 | 2013–2014 |